IP Library Granted Patent US 10,603,510
Granted Patent B2
US 10,603,510 · App. 16/102,063 · Granted Mar 31, 2020

Surgically positioned neutron flux activated high energy therapeutic charged particle generation system

Inventors: John H. Nelson (East McKeesport, PA); Michael D. Heibel (Harrison City, PA)
Assignee: Westinghouse Electric Company LLC
A61N5/10A61K41/009A61N2005/109A61N2005/1094A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,603,510
App. No.
16/102,063
Granted
Mar 31, 2020
Kind
B2
Abstract

A process for treating highly localized carcinoma cells that provides precise positioning of a therapeutic source of highly ionizing but weakly penetrating radiation, which can be shaped so that it irradiates essentially only the volume of the tumor. The intensity and duration of the radiation produced by the source can be activated and deactivated by controlling the neutron flux generated by an array of electrically controlled neutron generators positioned outside the body being treated. The energy of the neutrons that interact with the source element can be adjusted to optimize the reaction rate of the ionized radiation production by utilizing neutron moderating material between the neutron generator array and the body. The source device may be left in place and reactivated as needed to ensure the tumor is eradicated without exposing the patient to any additional radiation between treatments. The source device may be removed once treatment is completed.

Claims (24)

1. A method of treating localized carcinoma cells in a body of an animal comprising the steps of:

implanting one or more devices in the body proximate to the localized carcinoma cells, the one or more devices comprising a therapeutic source that comprises a material selected from the group consisting of B 4 C, P-31 and combinations thereof that is substantially nonradioactive when not exposed to a neutron source below a given activity, but becomes a source of highly ionizing but weakly penetrating radiation when exposed to a neutron field at or above the given activity;

irradiating the therapeutic source from outside the body with a neutron field at or above the given activity for a prescribed period of time,

wherein the one or more devices has a surface area such that the localized carcinoma cells are affected by the radiation; and

repeating the irradiating step at prescribed intervals.

2. The method of treating localized carcinoma cells of claim 1 wherein the therapeutic source of highly ionizing but weakly penetrating radiation comprises B 4 C, or P-31.

3. The method of treating localized carcinoma cells of claim 1 wherein the B 4 C is enriched in B-10 content.

4. The method of treating localized carcinoma cells of claim 1 wherein the therapeutic source of highly ionizing but weakly penetrating radiation is configured so it substantially only irradiates the carcinoma cells.

5. The method of treating localized carcinoma cells of claim 4 wherein a radiation shield material that shields at least some of the highly ionizing radiation, but is substantially transparent to neutrons, is formed on a side of the therapeutic source of the one or more devices such that the radiation shield material is not facing the carcinoma cells.

6. The method of treating localized carcinoma cells of claim 1 wherein the implanting step includes the step of surgically implanting the therapeutic source approximately on the carcinoma cells.

7. The method of treating localized carcinoma cells of claim 1 wherein the step of irradiating the therapeutic source includes the step of using an electric neutron generator to irradiate the therapeutic source.

8. The method of treating localized carcinoma cells of claim 7 wherein the electric neutron generator is a Neutristor.

9. The method of treating localized carcinoma cells of claim 7 wherein the electric neutron generator includes a plurality of electric neutron generators positioned around the body to irradiate the therapeutic source from different angles.

10. The method of treating localized carcinoma cells of claim 7 including the step of using a neutron moderating material between the electric neutron generator and the therapeutic source to adjust the neutron energy to optimize the highly ionizing, but weakly penetrating radiation produced by the therapeutic source.

11. The method of treating localized carcinoma cells of claim 10 wherein the neutron moderating material comprises D 2 O or C.

12. The method of treating localized carcinoma cells of claim 10 wherein the step of using the neutron moderating material includes the step of placing the neutron moderating material outside the body.

13. The method of treating localized carcinoma cells of claim 1 including the step of leaving the one or more devices comprising the therapeutic source within the body between treatments of treating the localized carcinoma cells.

14. The method of treating localized carcinoma cells of claim 13 including the step of removing the one or more devices comprising the therapeutic source from the body once treatment of the localized carcinoma cells is completed.

15. The method of treating localized carcinoma cells of claim 1 wherein the one or more devices comprising the therapeutic source comprises one or more very thin disks or plates in the order of a micron's thickness with a sufficient combined surface area to ensure the entire volume of localized carcinoma cells will be affected by the highly ionizing but weakly penetrating radiation when one or more of the disks or plates are emplaced around the carcinoma cells and irradiated with the neutron field.

16. The method of treating localized carcinoma cells of claim 1 wherein the therapeutic source is configured from a material that produces high energy alpha or beta particles and either no or low energy gamma radiation.

17. The method of treating localized carcinoma cells of claim 16 wherein the therapeutic source material is insoluble in water, non-toxic to the body and has short half-lives.

18. The method of treating localized carcinoma cells of claim 1 including the step of using a gamma spectrometer to monitor the intensity of gamma radiation emitted by a product of the neutron radiation of the therapeutic source material while a charged particle production rate can be monitored while the neutron irradiation is occurring.

19. The method of treating localized carcinoma cells of claim 18 using the monitored intensity of the gamma radiation and neutron activity of the neutron field to determine a radiation dose that has been applied to the body.

20. The method of treating localized carcinoma cells of claim 19 controlling the intensity of the neutron field based on the monitored gamma intensity and the radiation dose.

Assignments (2)
SECURITY INTEREST Recorded Jan 26, 2024
From: WESTINGHOUSE ELECTRIC COMPANY LLC; BHI ENERGY I SPECIALTY SERVICES LLC; STONE & WEBSTER, L.L.C. (FORMERLY STONE & WEBSTER, INC.)
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 066373/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2018
From: NELSON, JOHN H.; HEIBEL, MICHAEL D.
To: WESTINGHOUSE ELECTRIC COMPANY LLC
Reel/Frame 046628/0908 →
Continuity (2)
Provisional Application 62545522 · Aug 15, 2017
Related Publication 20190054313A1 · Feb 21, 2019
Cited By (1)
US 12,245,355